This is an excerpt of a 2,027-word article in the Nov. 4, 2019 issue of THE DARK REPORT (TDR). The full article is available to members of The Dark Intelligence Group.
CEO SUMMARY: Under a new federal rule in effect this month, all healthcare providers—including clinical laboratories and pathology groups—will need to scour the records of all officers, directors, and affiliates to identify any that have had negative dealings or been involved in Medicare fraud cases with CMS or other federal enforcement agencies. Under the rule, the Medicare program is likely to target labs that test for drugs of abuse, such as opioids, and that do genetic testing, said a lawyer who has studied the rule.
AS OF NOV 4, 2019, A NEW FEDERAL MEDICARE RULE TAKES EFFECT that can bring both benefits and headaches to the nation’s clinical laboratories and anatomic pathology groups.
The rule, Program Integrity Enhancements to the Provider Enrollment Process, is a long-overdue step to help federal officials identify individuals, investors, managers, and others who have been involved in Medicare fraud cases or who were associated with entities that owe Medicare fines that have not been paid.
When a provider enrolls or re-enrolls in Medicare, Medicaid, or the Children’s Health Insurance Program (CHIP), the rule requires that the provider disclose certain affiliates as the rule defines. In this process, however, there are pitfalls to avoid for unwary clinical labs and pathology groups. (See “Labs Must Respond to New CMS Anti-Fraud Rule,” TDR, Oct. 14, 2019.)
For starters, one attorney familiar with the rule predicted that federal officials would target providers such as clinical laboratories that Medicare has sanctioned in the past. The attorney, Courtney G. Tito, a member of the law firm of McDonald Hopkins, said the federal Centers for Medicare and Medicaid Services (CMS) will seek to identify labs or other providers engaged in such behavior.
“I believe CMS will use data analytics to target providers that are a high enforcement priority and have affiliations with a sanctioned event,” she stated. “This will probably be most true for those labs that run molecular and genetic tests, toxicology tests, and that do testing for drugs of abuse, such as opioids.” Tito represents healthcare providers, including clinical laboratories and pathology groups, in cases involving enrollment revocations, federal and private audits and disputes, and reimbursement issues.
“CMS will likely target toxicology labs and any lab doing anything associated with opioids,” Tito said in an interview with The Dark Report. “Also, CMS probably will target some genetic testing labs because those labs have been targeted recently for federal enforcement.”
In September, 2019, the federal Department of Justice (DOJ) announced the results of Operation Double Helix, an investigation that led the DOJ to charge 35 individuals in a $2.1 billion genetic testing scam. At least six lab owners were among those indicted in the Medicare fraud case. (See, “DOJ Charges 35 Individuals in $2.1 Billion Genetic Testing Scam,” TDR, Oct. 14, 2019.)
“My guess is that those types of labs would be the areas that CMS would target, but we don’t know that yet—at least not for certain,” added Tito. “It’s logical that CMS would begin with those labs because toxicology labs and opioid testing are prevalent in enforcement now and some of the labs have been cited in recent years.”
As a result of asking federal officials about how CMS identifies clinical laboratories, pathology groups, and other providers that could run afoul of the rule, Tito has learned that CMS uses data analytics to select such providers for further scrutiny. Accordingly, she said, it is likely that CMS will use the same process to determine the initial providers that need to respond to requests for more information under the rule. But Tito is concerned about how CMS will use such data analytics tools.
“Using data analytics can be worrisome because what parameters will CMS use when programming these systems?” she asked. “It’s not entirely clear from the commentary that CMS published with the rule how federal officials will use data to identify labs or other providers for enforcement.
Choice of Data Points to Identify Possible Targets
“The problem is that there are no real standards or requirements for what data analytics CMS will use and which data points it will use for its analysis,” she added. “For this process, federal officials can choose whatever data points they want.”
One data point that CMS could use is to review the list of individuals, clinical labs, pathology groups, and other providers that have been excluded from federal healthcare programs, she suggested. “The OIG exclusion lists would be a great place to start to match up the individuals and the entities that have been excluded from participation in the past,” stated Tito.
“Also, any company or entity that’s had a payment suspension, and any provider that has an uncollected overpayment from Medicare, Medicaid, or CHIP, also could be a target,” she continued.
The problem with going after labs and providers that have been targeted in the past is that most providers file appeals when facing payment suspensions from federal healthcare programs. But appeals take so long that many labs and providers do not survive the appeals process if their revenue depends heavily on federal reimbursement, Tito said. Such appeals usually take anywhere from three to 10 years and sometimes run longer, she added.
Another area of concern about the rule is that it imposes a significant burden on all healthcare providers to review the records of all “affiliations,” over the past five years. This review is to include officers and directors to identify any administrators that Medicare, Medicaid, or CHIP has sanctioned for any kind of Medicare fraud case, Tito said.
The rule requires clinical labs, pathology groups, and other healthcare providers to review what CMS calls “all required disclosable events” for each officer and director and all of its affiliates over the past five years, Tito explained.
Undue Risk of Fraud, Waste
After providers submit that information, CMS will review the facts to determine if that provider poses an undue risk of fraud, waste, or abuse based on any of its relationships with companies or individuals that CMS has sanctioned, she explained.
If any individuals or companies have ever been sanctioned for a Medicare fraud case, the lab or pathology group would need to disclose that information to CMS, she said.
“The rule also creates new revocation and denial authorities in an effort to stop waste, fraud, and abuse, including increased re-enrollment bars,” she wrote in a client alert last week, adding that the new rule imposes another burden on providers to maintain information on any affiliations it has had with excluded individuals or companies.
“The final rule imposes a five-year look-back on affiliations, meaning a provider will need to obtain and maintain all required disclosable events from each affiliation and provide that information to CMS for review,” she added. (See “Labs Must Respond to New CMS Anti-Fraud Rule,” TDR, Oct. 14, 2019.)
“It’s not so much that healthcare providers have criminal exposure, but one aim of the rule is to prevent criminal behavior through new enrollment rules,” Tito said.
“CMS is trying to weed out the people who try to shortcut the process to enroll in Medicare, Medicaid, or CHIP, or to re-enroll in any of these programs under different names.
“It’s not infrequent that after CMS cites owners, operators, corporate officers, directors, and other executives at clinical lab companies, these same individuals form other corporate entities that operate in a fraudulent manner,” she commented.
“But, in trying to short-circuit this behavior, CMS is creating a burdensome and costly process for all good providers—including those providers who have always been compliant,” she stated. “This new process basically requires providers to be private investigators. Under the rule, providers have to dig through all of their direct and indirect affiliations to see if CMS has sanctioned any of them.”
Burden for Providers
In a commentary, CMS acknowledged that complying with the rule will be burdensome for providers. It therefore adopted a phased-in approach to enforcement of this section of the new rule. In the initial phase, CMS will send requests to targeted providers and those providers will need to comply with the rule fully. Tito suggests, however, that clinical laboratories and anatomic pathology groups start preparing now and suggests several steps for doing so.
Contact Courtney Tito at 561-472-2121 or email@example.com.
Is your lab preparing to comply with the new CMS rule? If so, please share your thoughts on the process in the comments below.